115 related articles for article (PubMed ID: 15224089)
21. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen failure within 2 years of radical prostatectomy predicts overall survival.
Hachiya T; Ichinose T; Hirakata H; Kawata N; Okada K; Takimoto Y
Int J Urol; 2006 Apr; 13(4):362-7. PubMed ID: 16734851
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
24. Antegrade radical retropubic prostatectomy with preliminary ligation of vascular pedicles in 614 consecutive patients.
Kawakami S; Fukui I; Yonese J; Okubo Y; Yamamoto S; Tsukamoto T; Ishikawa Y
Jpn J Clin Oncol; 2007 Jul; 37(7):528-33. PubMed ID: 17720739
[TBL] [Abstract][Full Text] [Related]
25. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
Jones TD; Koch MO; Bunde PJ; Cheng L
BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012
[TBL] [Abstract][Full Text] [Related]
26. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
27. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
28. [Pathological stage T3 prostate cancer after radical prostatectomy: a retrospective study of 246 cases].
Roche JB; Malavaud B; Soulié M; Cournot M; Gamé X; Mazerolles C; Bachaud JM; Plante P; Rischmann P
Prog Urol; 2008 Oct; 18(9):586-94. PubMed ID: 18986631
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
Smith JA; Chan RC; Chang SS; Herrell SD; Clark PE; Baumgartner R; Cookson MS
J Urol; 2007 Dec; 178(6):2385-9; discussion 2389-90. PubMed ID: 17936849
[TBL] [Abstract][Full Text] [Related]
30. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.
Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM
BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
[TBL] [Abstract][Full Text] [Related]
32. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2001 Aug; 166(2):416-9. PubMed ID: 11458039
[TBL] [Abstract][Full Text] [Related]
33. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
35. Effect of perioperative blood transfusion on prostate cancer recurrence.
Ford BS; Sharma S; Rezaishiraz H; Huben RS; Mohler JL
Urol Oncol; 2008; 26(4):364-7. PubMed ID: 18367097
[TBL] [Abstract][Full Text] [Related]
36. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
37. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
38. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
39. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
40. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
